Evicore Cardiac Imaging Guidelines V19.0
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Cardiac CT - Quantitative Evaluation of Coronary Calcification
Clinical Appropriateness Guidelines: Advanced Imaging Appropriate Use Criteria: Imaging of the Heart Effective Date: January 1, 2018 Proprietary Date of Origin: 03/30/2005 Last revised: 11/14/2017 Last reviewed: 11/14/2017 8600 W Bryn Mawr Avenue South Tower - Suite 800 Chicago, IL 60631 P. 773.864.4600 Copyright © 2018. AIM Specialty Health. All Rights Reserved www.aimspecialtyhealth.com Table of Contents Description and Application of the Guidelines ........................................................................3 Administrative Guidelines ........................................................................................................4 Ordering of Multiple Studies ...................................................................................................................................4 Pre-test Requirements ...........................................................................................................................................5 Cardiac Imaging ........................................................................................................................6 Myocardial Perfusion Imaging ................................................................................................................................6 Cardiac Blood Pool Imaging .................................................................................................................................12 Infarct Imaging .....................................................................................................................................................15 -
The Role of Multimodality Cardiac Imaging in the Management Of
CVIA The Role of Multimodality Cardiac REVIEW ARTICLE pISSN 2508-707X / eISSN 2508-7088 Imaging in the Management https://doi.org/10.22468/cvia.2017.00038 CVIA 2017;1(3):177-192 of Patients with Atrial Fibrillation Jung Im Jung Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea Received: March 6, 2017 Atrial fibrillation (AF) is the most common arrhythmia and is an independent risk factor for Revised: June 22, 2017 stroke, heart failure, and death. The prevalence of AF is expected to increase in the future Accepted: June 28, 2017 due to increasing life expectancy. In this review, we describe and evaluate the utility of ad- Corresponding author vanced cardiovascular imaging modalities, including echocardiography, cardiac computed Jung Im Jung, MD, PhD tomography, and cardiac magnetic resonance imaging, to provide novel insights into the Department of Radiology, pathogenesis, prediction, and natural history of AF. Moreover, cardiovascular imaging has Seoul St. Mary’s Hospital, become an integral part of the pre-procedural assessment, procedural management, and College of Medicine, follow-up of patients undergoing catheter-based ablation. We believe that knowledge and The Catholic University of Korea, proper use of these cardiovascular imaging modalities will enhance the successful treatment 222 Banpo-daero, Seocho-gu, and management of patients with AF. Seoul 06591, Korea Tel: 82-2-2258-1435 Key words Atrial fibrillation · Catheter ablation · Echocardiography · Fax: 82-2-599-6771 Multidetector computed tomography · Magnetic resonance Imaging. E-mail: [email protected] INTRODUCTION treat AF. Cardiovascular imaging has become an integral part of the pre-procedural assessment, procedural management, and Atrial fibrillation (AF) is the most common arrhythmia man- follow-up of patients undergoing catheter-based left atrium (LA) aged in clinical practice. -
2018 Guideline Document on Chagas Disease
GUIDELINES AND STANDARDS Recommendations for Multimodality Cardiac Imaging in Patients with Chagas Disease: A Report from the American Society of Echocardiography in Collaboration With the InterAmerican Association of Echocardiography (ECOSIAC) and the Cardiovascular Imaging Department of the Brazilian Society of Cardiology (DIC-SBC) Harry Acquatella, MD, FASE (Chair), Federico M. Asch, MD, FASE (Co-Chair), Marcia M. Barbosa, MD, PhD, FASE, Marcio Barros, MD, PhD, Caryn Bern, MD, MPH, Joao L. Cavalcante, MD, FASE, Luis Eduardo Echeverria Correa, MD, Joao Lima, MD, Rachel Marcus, MD, Jose Antonio Marin-Neto, MD, PhD, Ricardo Migliore, MD, PhD, Jose Milei, MD, PhD, Carlos A. Morillo, MD, Maria Carmo Pereira Nunes, MD, PhD, Marcelo Luiz Campos Vieira, MD, PhD, and Rodolfo Viotti, MD*, Caracas, Venezuela; Washington, District of Columbia; Belo Horizonte and Sao~ Paulo, Brazil; San Francisco, California; Pittsburgh, Pennsylvania; Floridablanca, Colombia; Baltimore, Maryland; San Martin and Buenos Aires, Argentina; and Hamilton, Ontario, Canada In addition to the collaborating societies listed in the title, this document is endorsed by the following American Society of Echocardiography International Alliance Partners: the Argentinian Federation of Cardiology, the Argentinian Society of Cardiology, the British Society of Echocardiography, the Chinese Society of Echocardiography, the Echocardiography Section of the Cuban Society of Cardiology, the Echocardiography Section of the Venezuelan Society of Cardiology, the Indian Academy of Echocardiography, -
Myocardial Perfusion Imaging (Revised Edition)
Publications · Brochures Myocardial Perfusion Imaging (Revised Edition) A Technologist’s Guide Produced with the kind Support of Editors Ryder, Helen (Dublin) Testanera, Giorgio (Rozzano, Milan) Veloso Jerónimo, Vanessa (Almada) Vidovič, Borut (Munich) Contributors Abreu, Carla (London) Koziorowski, Jacek (Linköping) Acampa, Wanda (Naples) Lezaic, Luka (Ljubljana) Assante, Roberta (Naples) Mann, April (South Hadley) Ballinger, James (London) Medolago, Giuseppe (Bergamo) Fragoso Costa, Pedro (Oldenburg) Pereira, Edgar (Almada) Figueredo, Sergio (Lisbon) Santos, Andrea (Alverca do Ribatejo) Geão, Ana (Lisbon) Vara, Anil (Brighton) Ghilardi, Adriana (Bergamo) Zampella, Emilia (Naples) Holbrook, Scott (Gray) Contents Foreword 4 Introduction 5 Borut Vidovič Chapter 1 State of the Art in Myocardial Imaging 6 Wanda Acampa, Emilia Zampella and Roberta Assante Chapter 2 Clinical Indications 16 Luka Lezaic Chapter 3 Patient Preparation and Stress Protocols 23 Giuseppe Medolago and Adriana Ghilardi EANM Chapter 4 Multidisciplinary Approach and Advanced Practice 35 Anil Vara Chapter 5 Advances in Radiopharmaceuticals for Myocardial Perfusion Imaging 42 James R. Ballinger and Jacek Koziorowski Chapter 6 SPECT and SPECT/CT Protocols and New Imaging Equipment 54 Andrea Santos and Edgar Lemos Pereira Chapter 7 PET/CT Protocols and Imaging Equipment (*) 62 April Mann and Scott Holbrook Chapter 8 Image Processing and Software 77 Sérgio Figueiredo and Pedro Fragoso Costa Chapter 9 Artefacts and Pitfalls in Myocardial Imaging (SPECT, SPECT/CT and PET/CT) 109 Ana Geão and Carla Abreu Imprint 126 n accordance with the Austrian Eco-Label for printed matters. Eco-Label with the Austrian for n accordance (*) Articles were written with the kind support Printed i Printed of and in cooperation with: 3 Foreword The EANM Technologist Committee was dural workflow and need to cooperate with created more than 20 years ago. -
PET/CT Evaluation of Cardiac Sarcoidosis
PET/CT Evaluation of Cardiac Sarcoidosis John P. Bois, MDa,*, Daniele Muser, MDb,1, Panithaya Chareonthaitawee, MDa KEYWORDS Cardiac sarcoidosis Positron emission tomography Fluorine-18 deoxyglucose KEY POINTS Sarcoidosis can involve the heart at with resultant significant morbidity and mortality. PET/CT is the most accurate method by which to diagnose cardiac sarcoidosis. Patient preparation prior to the PET/CT cardiac sarcoid study is critical to ensure diagnostic images are obtained. PET/CT detection of both active inflammation and scar has diagnostic, prognostic, and therapeutic importance. Ongoing areas of research include the use of PET to quantify the extent of myocardial inflammation and the discrepancies in myocardial blood flow in the cardiac sarcoidosis population. INTRODUCTION experiencing spontaneous remission and the remaining one-third developing either a stable or The increasing implementation of advanced car- progressive course.3 diovascular imaging in the form of cardiac PET/ The rate of cardiac involvement by sarcoidosis, CT has had a significant impact on the manage- otherwise termed CS, is variable and ranges ment of cardiac sarcoidosis (CS), one that con- from 20% to 75%.4,5 Furthermore, CS accounts tinues to evolve. Sarcoidosis is characterized for one-fourth of sarcoid-related mortality in the histologically by the presence of noncaseating United States and upward of 85% of death attrib- granulomas, with a predilection for the pulmonary uted to sarcoidosis in the Japanese population.4,6 system but with the ability to involve nearly every The high rate of involvement of the cardiovascular organ. Although the development of sarcoidosis system by sarcoidosis coupled with the potential is believed the sequelae of an exaggerated im- lethal outcomes has rendered accurate and timely mune or inflammatory response to an inciting in- diagnosis of this disease entity as imperative to fectious or environmental trigger, the specific patient care. -
Clinical Review Karen Bleich NDA 020351 Supplement 44 (CCTA) Visipaque (Iodixanol)
Clinical Review Karen Bleich NDA 020351 Supplement 44 (CCTA) Visipaque (iodixanol) CLINICAL REVIEW Application Type Supplemental New Drug Application Application Number(s) NDA 020351 s44 Priority or Standard Priority Submit Date(s) October 6th, 2016 Received Date(s) October 18th, 2016 PDUFA Goal Date April 5th, 2017 Division/Office Division of Medical Imaging Products/Office of Drug Evaluation IV Reviewer Name(s) Karen Bleich, MD Review Completion Date March 10th, 2017 Established Name Iodixanol (Proposed) Trade Name Visipaque Injection Applicant GE Healthcare Formulation(s) 320 mgI/mL Dosing Regimen 70-80 mL main bolus volume (does not include optional test bolus volume of 20 mL) at a flow rate of(b) (4) mL/s, followed by 20 mL saline flush Applicant Proposed For use in coronary computed tomography angiography (CCTA) to Indication(s)/Population(s) assist in the diagnostic evaluation of patients with suspected coronary artery disease. Recommendation on Approval Regulatory Action Recommended For use in coronary computed tomography angiography (CCTA) to Indication(s)/Population(s) assist in the diagnostic evaluation of patients with suspected (if applicable) coronary artery disease. CDER Clinical Review Template 2015 Edition 1 Reference ID: 4068412 Clinical Review Karen Bleich NDA 020351 Supplement 44 (CCTA) Visipaque (iodixanol) Table of Contents Glossary ........................................................................................................................................... 8 1 Executive Summary .............................................................................................................. -
ICD-10 and Cardiology Steven M
ICD-10-CM and Cardiology Steven M. Verno, CMBSI, CEMCS, CMSCS, CPM-MCS Page 1 of 24 ICD-10 and Cardiology Steven M. Verno, CMBSI, CEMCS, CMSCS, CPM-MCS Note: ICD-9-CM and ICD-10 are owned and copyrighted by the World Health Organization. The codes in this guide were obtained from the US Department of Health and Human Services, NCHS website. This guide does not contain ANY legal advice. This guide shows what specific codes will change to when ICD-9-CM becomes ICD-10-CM. This guide does NOT discuss ICD-10-PCS. This guide does NOT replace ICD-10-CM coding manuals. This guide simply shows a practice what ICD-10-CM will look like within their specialty. The intent is to show that ICD-10 is not scary and it is not complicated. This guide is NOT the final answer to coding issues experienced in a medical practice. This guide does NOT replace proper coding training required by a medical coder and a medical practice. Images or graphics were obtained from free public domain internet websites and may hold copyright privileges by the owner. This guide was prepared for Free. If you paid for this, demand the return of your money! If the name of the original author, Steve Verno, has been replaced, it is possible that you have a thief on your hands. Page 2 of 24 For the past thirty-one (31) years, we have learned and used ICD-9-CM when diagnosis coding for our providers. ICD stands for International Classification of Diseases. -
Myocardial Perfusion Imaging with PET
SPECIAL CONTRIBUTION Myocardial Perfusion Imaging with PET Markus Schwaiger Nuklearmedizinische Klinik und Poliklini/çDer Technischen Universitdt Munchen, Klini/wm Rechts der Isar, Munich, Germany SPEC!' (5). PET spatial resolution is superior to that of AlthoughSPECThas become an acceptedimagingtechnique SPECT, resulting in superior image quality and less partial formyocardialperfusionstudies,thereare severaladvantages volume effect (5). Most PET images are processed with a to evaluatingcoronaryarterydisease (CAD)withPET.CADis a spatial resolution of about 6—10mm, as compared with complex, dynamic disease and quantitativemeasurements of 10—15mm for SPECF image reconstruction. myocardialbloodflowby PET can improvethe fUnCtiOnalchar The majoradvantageof PET is its ability to correct for acterizationof CAD.The majoradvantage of PET over SPECT attenuation.Traditionalmyocardialperfusionimagingwith is @rtsabilityto provideattenuation-correctedimages, whichde single-photon radiotracers such as 201'flposes significant creases incidenceof attenuation artifactsand increases spea challenges in avoiding or identifying and correcting for flcfty.Myocardialpertusion imagingwithPET can also provide moreaccurateinformationon localizationofdisease, as wellas attenuation artifacts, particularly those that involve the quantitativeassessment, inabsolutevalues, ofmyocardialblood inferior wall in male patients and the anterior wall in female flow.The measurement ofregionalflowreserve allowsforphys patients (6,7). iologiccharacterizationof stenosis severity, -
Time-Of-Flight PET Map out Goals by Joel S
Volume 3, Issue 4 FALL 2006 pet center of excellence newsletter PET COE Board Meets with Industry Advisory Group to Time-of-Flight PET Map Out Goals By Joel S. Karp, PhD he idea to use time-of-flight (TOF) information in PET image reconstruction By James W. Fletcher, MD Twas originally proposed in the 1960s at a very early stage in the development of President, PET Center of Excellence positron imaging. By the early 1980s, fully functional TOF PET systems had been built, An inaugural meet- not long after the first conventional PET systems were completed. Why then did it take ing was held recently so long to introduce a clinical TOF PET scanner, and how does it compare to the first in Chicago between the TOF PET instruments built 25 years ago? PET Center of Excel- Time-of-Flight Theory lence Board of Directors The concept of time-of-flight means simply that for each annihilation event, we note (BOD) and the Industry the precise time that each of the coincident photons is detected and calculate the dif- Advisory Group (IAG). ference. Since the closer photon will arrive at its detector first, the difference in arrival The meeting was very times helps pin down the location of the annihilation event along the line between the James W. Fletcher well attended with rep- two detectors. resentation from a large To understand why this information is useful, we need to recall that normally in cross-section of industry. PET we collect line pair data at many angles and create tomographic images through The interaction and discussion at the con- traditional filtered back-projection or through an iterative series of back- and forward- joint morning meeting was lively and infor- projection steps. -
Atrium Health Delineation of Privileges Specialty of Radiology
ATRIUM HEALTH DELINEATION OF PRIVILEGES SPECIALTY OF RADIOLOGY Print Name YES NO** I have participated in direct patient care in the hospital setting within the past two (2) years. **If the answer is No, please do not complete this form. Contact the Medical Staff Office at (704) 355-2147 for additional instructions regarding the required proctoring process. Initial appointment Reappointment Updated DOP Request for Clinical Privileges To be eligible for core privileges in Radiology, the applicant must meet the following qualifications: If the applicant is not currently certified in Radiology by the American Board of Medical Specialties (ABMS) or the American Osteopathic Association (AOA) the applicant must: 1. Provide documentation of successful completion of an ACGME or AOA accredited Radiology training program, within the past five (5) years; AND 2. Provide documentation of the performance and interpretation of at least five-thousand (5,000) imaging tests in the past two (2) years. Applicants have the burden of producing information deemed adequate by the hospital for proper evaluation of current competence, and other qualifications and for resolving any doubts; OR If the applicant is currently certified in Radiology by the American Board of Medical Specialties (ABMS) or the American Osteopathic Association (AOA), the applicant must: 1. Provide documentation of general pediatric certification from the American Board of Medical Specialties or the American Osteopathic Association (AOA); AND 2. Provide documentation of the performance and interpretation of at least five-thousand (5,000) imaging tests in the past two (2) years. Applicants have the burden of producing information deemed adequate by the hospital for proper evaluation of current competence, and other qualifications and for resolving any doubts. -
Cardiac Radiology)
CAE002-b F-18 FDG PET/CT and MRI In the Diagnosis and Management of Cardiac Sarcoidosis Education Exhibits Location: CA Community, Learning Center Participants Richard Anthony R. Coulden MD (Presenter): Nothing to Disclose Emer Sonnex : Nothing to Disclose Hefin Jones FRCR : Nothing to Disclose Indrajeet Das MBBCh, MRCP : Nothing to Disclose Jonathan Thomas Abele MD : Nothing to Disclose TEACHING POINTS In patients with established non-cardiac sarcoidosis, both FDG PET/CT and cardiac MRI can be used to diagnose cardiac involvement. We will learn how and why: 1. FDG PET/CT identifies active disease and can be used in both diagnosis and management. Serial PET allows assessment of response to immunosuppressive treatment. 2. Cardiac MRI identifies myocardial edema and scar. It has proven value in diagnosis but its role in monitoring disease in response to treatment is unclear. 3. Cardiac MRI provides additional value in assessment of ventricular volumes and function and maybe a helpful surrogate in monitoring treatment response. 4. FDG PET/CT and MRI are complementary techniques. TABLE OF CONTENTS/OUTLINE 1. Criteria for clinical diagnosis of cardiac sarcoidosis (Japanese Ministry of Health and Welfare) 2. How to use FDG PET/CT for inflammatory cardiac imaging 3. How to use cardiac MRI for infiltrative cardiomyopathies 4. Relative roles of Cardiac MRI and FDG PET/CT in: a. the imaging diagnosis of cardiac sarcoidosis b. follow-up of disease activity and response to immunosuppressive treatment. CAE004-b Dynamic Myocardial Perfusion Imaging by 3rd Generation Dual-Source CT Education Exhibits Location: CA Community, Learning Center Participants Marisa Marjolein Lubbers MD (Presenter): Nothing to Disclose Adriaan Coenen MD : Nothing to Disclose Akira Kurata : Nothing to Disclose Marcel L. -
Perioperative Stress Testing: the New High Risk Paradigm
medigraphic Artemisaen línea E A NO D NEST A ES Mexicana de IC IO EX L M O G O I ÍA G A E L . C C O . C Revista A N A T Í E Anestesiología S G S O O L C IO I S ED TE A ES D M AN EXICANA DE PROFESORES EXTRANJEROS Vol. 32. Supl. 1, Abril-Junio 2009 pp S198-S206 Perioperative stress testing: The new high risk paradigm Marc A. Rozner, PhD, MD* * Professor of Anesthesiology and Perioperative Medicine. Professor of Cardiology The University of Texas MD Anderson Cancer Center. Houston, TX [email protected] INTRODUCTION Each scenarios (i.e.; should have been tested but was not; did not need the test but was tested anyway, got tested For sometime, anesthesiologists have been asked to assist and intervention) is accompanied by financial and medi- in the assignment of risk for an operative procedure, espe- cal complication issues that are beyond the scope of this cially the patient with cardiac disease. For most of these talk. It is important to keep in mind that every medical test patients, the preoperative assessment involves a decision and procedure has a potential downside – a significant about getting a stress test and dealing with the results. But aspect to the patient with a positive stress test who has a there is little data to support this practice, and recent events stroke during the follow-up, clean cardiac catheterization. suggesting that mechanical coronary artery intervention In their Guideline Update for exercise testing, the ACC / actually increases perioperative risk of MI and death have AHA quote a rate for myocardial infarction and / or death muddied the perioperative water.